Alzamend Neuro, Inc (NASDAQ: ALZN) stock price saw a steep rise today off the back of a positive response from the FDA for the development of AL002, a cell-based therapeutic vaccine that aims to bolster the immune system in the face of Alzheimer’s disease.Â
Alzamend, a clinical-stage biopharmaceutical company, are specialists in the treatment of neurodegeneration and psychiatric disorders. Stock prices soared in mid-market trading today after a public announcement that the company received a written reply to its meeting request regarding the movement of AL002.
CEO of Alzamend Stephan Jackman is thoroughly pleased with the progress of the new Alzheimer’s treatment:
“We appreciate the thorough and meaningful response from the FDA, which provides us with the information and clarity needed to submit the IND application to initiate a clinical trial for AL002.”Â
Following with:Â
“We appreciate the FDA’s recommendations, guidance and other helpful advice. We plan to augment our proposed clinical trial protocols and proceed accordingly.”
With clinical trials on the horizon, this is a promising time for Alzamend, it’s investors, and Alzheimers sufferers alike. Alzamend hopes to file the necessary IND by the end of November 2021, paving a clear route for clinical trials in the first quarter of 2022.
The progress of the cell-based therapeutic vaccine made an impressive impact on the market today, with gains reaching highs of 35% and the price currently teetering over the $3 level.
Should You Invest in Alzamend Neuro Shares?
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now
